• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Dr Anderson on the FDA ODAC Decision Regarding Cilta-Cel in R/R Multiple Myeloma

by | Apr 29, 2024 | Uncategorized

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma. Read More

Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma

by | Apr 25, 2024 | Uncategorized

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma. Read More

Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma

by | Apr 25, 2024 | Uncategorized

Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma. Read More

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

by | Apr 25, 2024 | Uncategorized

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications. Read More

Nurse Suggests Questions to Ask Before Carvykti Treatment for Myeloma

by | Apr 24, 2024 | Uncategorized

Source: CureToday articles With Carvykti now approved for pretreated myeloma, there are conversations that patients should have with their providers before treatment, a nurse said. Read More

Carvykti Provides Good Long-Term Quality of Life in Pretreated Myeloma

by | Apr 24, 2024 | Uncategorized

Source: CureToday articles Patients with heavily pretreated myeloma tended to have “really amazing results” with the CAR-T cell therapy, Carvykti. Read More
« Older Entries
Next Entries »

Recent Content

  • Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
  • Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
  • What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
  • Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
  • Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
  • Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
  • Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT